SparingVision is pleased to announce that it will present a poster highlighting the Company’s recent research into ocular diseases and its lead gene therapy treatment, SPVN06, at the American Society of Gene and Cell Therapy (‘ASGCT’) 24th Annual Meeting
Paris, May 11, 2021 – SparingVision (or the ‘Company’), a genomic medicine company developing vision saving treatments for ocular diseases, is pleased to announce that it will present a poster highlighting the Company’s recent research into ocular diseases and its lead gene therapy treatment, SPVN06, at the American Society of Gene and Cell Therapy (‘ASGCT’) 24th Annual Meeting. Details of the poster can be found below.
Poster: Rod-Derived Cone Viability Factor Provides Trophic Support for Cone Photoreceptors in a Pig Model of Retinitis Pigmentosa(Abstract #552)
SparingVision administered SPVN06 via subretinal injection in pigs in their first postnatal week and evaluated its effects on cone morphology, Dr Jennifer Noel, from the University of Louisville will present the poster on Tuesday 11 May 2021 from 08:00 AM to 10:00 AM EST. The administration of the AAV SPVN06 therapy was found to preserve cone morphology as well as preserve m-opsin expression in cone segments. It also leads to a greater expression of rod-derived cone viability factor (‘RdCVFL’).
The abstract of the presentation is available on the ASGCT website.
SparingVision is a genomic medicines company, translating pioneering science into vision-saving treatments.
Founded to advance over 20 years of world-leading ophthalmic research from its scientific founders at the Paris Vision Institute, SparingVision is leading a step shift in how ocular diseases are treated, moving beyond single gene correction therapies. At the heart of this is a pipeline of gene independent treatments for rod-cone dystrophies. Lead products, SPVN06 and SPVN20, address mid and late stages of retinitis pigmentosa (RP)respectively. RP is the most common inherited retinal disease affecting two million people worldwide. These novel medicines could form the basis of a suite of new sight-saving treatments with potential applications across many other retinal diseases, regardless of genetic cause.
The Company is supported by a strong, internationally renowned team who aim to harness the potential of genomic medicine to deliver new treatments to all ocular disease patients as quickly as possible.
SparingVision has raised €60 million to date and its investors include 4BIO Capital, Bpifrance, Foundation Fighting Blindness (US), Fondation Voir & Entendre, UPMC Enterprises, Jeito Capital and Ysios Capital. For more information, please visit www.sparingvision.com.